{"prompt": "['MC1575', '56', 'Amendment 2', '16.4', 'Monitoring', 'The principal investigator and the study statistician will review the study periodically to', 'identify accrual, toxicity, and any endpoint problems that might be developing. In', 'addition, this study will be monitored according to the Mayo Clinic Cancer Center', '(MCCC) Data Safety Monitoring Plan that is currently in place. The MCCC Data Safety', 'Monitoring Board (DSMB) is responsible for reviewing safety data for this trial at least', 'twice a year, based on reports provided by the MCCC Statistical Office.', '16.41 Adverse Event Stopping Rules', 'NOTE: NCI CTCAE v4.0 will be used to determine grading for adverse event', 'stopping rules.', 'If 2 or more of the first 5 patients enrolled or 30% or more of the patients', 'enrolled thereafter develop a grade 4 or severer non-hematologic toxicity (except', 'for hypertension) or grade 4 or severer hematologic toxicity that are considered', 'possibly, probably, or definitely related to treatment, enrollment to the study will', 'be suspended. The study team will review all adverse event data. A trial', 'recommendation will be formulated and presented to the MCCC DSMB - the', 'study may permanently close or may re-open to accrual after CTEP and IRB', 'approvals of protocol/consent form modifications.', '16.5', 'Results Reporting on ClinicalTrials.gov', 'At study activation, this study will have been registered within the \"ClincialTrails.gov\"', 'website. The Primary and Secondary Endpoints along with other required information for', 'this study will be reported on www.ClinicalTrials.gov. For purposes of timing of the', 'Results Reporting, the initial estimated completion date for the Primary Endpoint of this', 'study is 3 years after the study opens to accrual. The definition of \"Primary Endpoint', 'Completion Date\" (PECD) for this study is at the time the last patient registered has been', 'followed for at least 6 months.', '16.6', 'Subset Analyses for Minorities:', '16.61 Study availability', 'This study will be available to all eligible patients, regardless of gender, race or', 'ethnic origin.', '16.62 Statistical analysis by subset', 'There is no information currently available regarding differential effects of this', 'regimen in subsets defined by race, gender, or ethnicity, and there is no reason to', 'expect such differences to exist. Therefore, although the planned analyses will', 'look for differences in treatment effect based on racial groupings, the sample size', 'is not increased in order to provide additional power for subset analyses.', '16.63 Regional population', 'The geographical region served by MCCC has a population which includes', 'approximately 3% minorities. Based on prior MCCC studies involving similar', 'disease sites, we expect about 3-5% of patients will be classified as minorities by', 'race and about 33% of patients will be women. Expected sizes of racial by', 'gender subsets are shown in the following table:', 'Protocol Version Date: :16Aug2018']['MC1575', '57', 'Amendment 2', 'Accrual Targets', 'Sex/Gender', 'Ethnic Category', 'Females', 'Males', 'Total', 'Hispanic or Latino', '0', '1', '1', 'Not Hispanic or Latino', '12', '12', '24', 'Ethnic Category: Total of all subjects', '12', '13', '25', 'Racial Category', 'American Indian or Alaskan Native', '0', '0', '0', 'Asian', '1', '1', '2', 'Black or African American', '0', '1', '1', 'Native Hawaiian or other Pacific Islander', '0', '0', '0', 'White', '11', '11', '22', 'Racial Category: Total of all subjects', '12', '13', '25', 'Ethnic', 'Hispanic or Latino - a person of Cuban, Mexican, Puerto Rican, South or Central', 'Categories:', 'American, or other Spanish culture or origin, regardless of race. The term \"Spanish', 'origin\" can also be used in addition to \"Hispanic or Latino.\"', 'Not Hispanic or Latino', 'Racial', 'American Indian or Alaskan Native - a person having origins in any of the original', 'Categories:', 'peoples of North, Central, or South America, and who maintains tribal affiliations or', 'community attachment.', 'Asian - a person having origins in any of the original peoples of the Far East,', 'Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China,', 'India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and', 'Vietnam. (Note: Individuals from the Philippine Islands have been recorded as Pacific', 'Islanders in previous data collection strategies.)', 'Black or African American - a person having origins in any of the black racial', 'groups of Africa. Terms such as \"Haitian\" or \"Negro\" can be used in addition to', '\"Black or African American.\"', 'Native Hawaiian or other Pacific Islander - a person having origins in any of the', 'original peoples of Hawaii, Guam, Samoa, or other Pacific Islands.', 'White - a person having origins in any of the original peoples of Europe, the Middle', 'East, or North Africa.', 'Protocol Version Date: :16Aug2018']\n\n###\n\n", "completion": "END"}